1. CRISPR/Cas9 screening: unraveling cancer immunotherapy's 'Rosetta Stone'.
- Author
-
Chen, Baoxiang, Deng, Yanrong, Ren, Xianghai, Zhao, Jianhong, and Jiang, Congqing
- Subjects
- *
KILLER cells , *CYTOTOXIC T cells , *GENETIC testing , *ROSETTA Stone , *MEDICAL screening - Abstract
Cancer immunotherapy has transformed the treatment landscape for numerous malignancies and is emerging as an increasingly revolutionary and promising approach for cancer treatment. Clustered regularly interspaced palindromic repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) screening, a potent tool for unbiased functional genomic screening, has unveiled novel molecular targets for cancer immunotherapy. CRISPR/Cas9 screening facilitates the identification of targets in both cancer cells and immune cells, including T and natural killer cells. Various CRISPR screening methods such as in vitro and in vivo screening, along with diverse techniques including CRISPR-ko, CRISPRi, and CRISPRa screening, are utilized for target identification across various cancer models. In vivo CRISPR screening replicates human cancer by preserving the native microenvironment and facilitating high-throughput analysis of intricate cancer processes. Clustered regularly interspaced palindromic repeats (CRISPR)-based technology, a powerful toolset for the unbiased functional genomic screening of biological processes, has facilitated several scientific breakthroughs in the biomedical field. Cancer immunotherapy has advanced the treatment of numerous malignancies that previously had restricted treatment options or unfavorable outcomes. In the realm of cancer immunotherapy, the application of CRISPR/CRISPR-associated protein 9 (Cas9)-based genetic perturbation screening has enabled the identification of genes, biomarkers, and signaling pathways that govern various cancer immunoreactivities, as well as the development of effective immunotherapeutic targets. In this review, we summarize the advances in CRISPR/Cas9-based screening for cancer immunotherapy and outline the immunotherapeutic targets identified via CRISPR screening based on cancer-type classification. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF